Eiger BioPharmaceuticals completes 1-for-30 reverse stock split effective Jan 5, 2024

Eiger BioPharmaceuticals, Inc.

Reverse stock split ratio of 1:30 approved by stockholders on Dec 28, 2023 and Board.
Effective at 11:59 p.m. ET on Jan 5, 2024; stock began split-adjusted trading Jan 8, 2024.
No fractional shares issued; cash paid in lieu based on Nasdaq closing price prior to effective date.
New CUSIP number 28249U204 assigned to common stock.

item 3.03 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 1.0

Eiger BioPharmaceuticals, Inc.: Amended charter to effect a one-for-thirty reverse stock split (effective 2024-01-05).

Change: charter amendment
Effective: 2024-01-05

Exact text from the filing

On December 28, 2023, the Board approved the Reverse Stock Split at a ratio of one-for-thirty. Following such approval, the Company filed an amendment to its Charter (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, with an effective time of 11:59 p.m. Eastern Time on January 5, 2024 (the “ Effective Time ”).

View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR

accession 0001193125-24-003855

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.